Early entrant protection in approval regulation: Theory and evidence from FDA drug review

Journal of Law, Economics, and Organization

Volumn 26, Issue 3, 2010, Pages 515-545

  Carpenter, Daniel ^a   Moffitt, Susan I ^a   Moore, Colin D ^a   Rynbrandt, Ryan T ^b   Ting, Michael M ^c   Yohai, Ian ^a   Zucker, Evan James ^d  

^a HARVARD UNIVERSITY   (United States)

^b Department of Geology and Environmental Science   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77958563386     PISSN: 87566222     EISSN: 14657341     Source Type: Journal    
DOI: 10.1093/jleo/ewp002     Document Type: Article

References (44)

1. Acemoglu, Daron, and Joshua Linn. 2005. "MarketSize and Innovation: Theory and Evidence from the Pharmaceutical Industry," 119 Quarterly Journal of Economics 1049-90.
2. Arnold, R. Douglas. 1990. The Logic of Congressional Action. New Haven, CT: Yale University
3. Press. Bartel, Ann, and Lacy Glenn Thomas. 1987. "Predation through Regulation," 30 Journal of Law and Economics 239-64.
4. Billingsley, Patrick. Probability and Measure. 2nd ed. New York: Wiley.
5. Brehm, John, and Scott Gates. 1997. Working, Shirking and Sabotage. Ann Arbor, MI: University of Michigan Press.
6. Breyer, Stephen. 1982. Regulation and Its Reform. Cambridge: Harvard University Press).
7. Burkholz, Herbert. 1994. The FDA Follies. New York: Basic Books. Carpenter
8. Daniel P. 2002. "Groups, the Media and Agency Waiting Costs: The Political Economy of FDA Drug Approval," 46 American Journal of Political Science 490-505.
9. -. 2004a. "The Political Economy of FDA Drug Approval: Processing, Politics and Lessons for Policy," Health Affairs 52-63.
10. -. 2004b. "Protection without Capture: Product Approval by a Politically Responsive, Learning Regulator," 98 American Political Science Review 613-31.
11. Carpenter, Daniel P, and Michael M. Ting. 2007. "Regulatory Errors with Endogenous Agendas," 51.4 American Journal of Political Science 835-52.
12. Comanor, William S. 1986. "The Political Economy of the Pharmaceutical Industry," 24 Journal of Economic Literature 1178-217.
13. DeGroot, Morris H. 1970. Optimal Statistical Decisions. New York: McGraw-Hill.
14. Di Masi, Joseph A. 1996. "A New Look at United States Drug Development and Approval Times," 3 American Journal of Therapeutics 1-11.
15. DiMasi, Joseph A, Ronald W. Hansen, Henry G. Grabowski, and Louis, Lasagna. 1991. "Cost of Innovation in the Pharmaceutical Industry," 10 Journal of Health Economics 107-42.
16. Dranove, David, and David, Meltzer. 1994. "Do Important Drugs Reach the Market Sooner?" 25 RAND Journal of Economics 402-23.
17. Epstein, Steven. 1996. Impure Science: AIDS, Activism, and the Politics of Knowledge. Berkeley: University of California.
18. General Accounting Office [GAO]. 1995. FDA Review Time for Drugs has Decreased in Recent Years. Washington, DC: GAO.
19. Gordon, Sanford. 1999. Managing Fairness. Ph.D. dissertation, Princeton University.
20. Grabowski, Henry G., and John M. Vernon. 1976. "Structural Effects of Regulation on Innovation in the Ethical Drug Industry," in Robert T. Masson and P. David Qualls, eds., Essays on Industrial Organization in Honor of Joe S. Bain. Cambridge, MA: Lippincott, Ballinger 181-205.
21. -. 1983. The Regulation of Pharmaceuticals. Washington, DC: AEI Press.
22. Heimann, C. F. Larry. 1997. Acceptable Risks: Politics, Policy and Risky Technologies. Ann Arbor, MI: University of Michigan.
23. Henderson, Rebecca, and I. Cockburn. 1996. "Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery," 27(1) RAND Journal of Economics 32-59.
24. Hinich, Melvin J., and Richard Staelin. 1980. Consumer Protection Regulation and the U.S. Food Industry. New York: Pergamon Press.
25. Karatzas, Ioannis, and Steven E. Shreve. 1991. Brownian Motion and Stochastic Calculus. 2nd ed. New York: Springer-Verlag.
26. Krause, George, and J. Kevin Corder. 2007. "Explaining BureaucraticOptimism: Theory and Evidence from U.S. Federal Executive Agency Macroeconomic Forecasts." 101 American Political Science Review 129-42.
27. Krause, George A., and James W. Douglas. 2005. "Institutional Design versus Reputational Explanations of Agency Performance: Evidence from U.S. Government Macroeconomic and Fiscal Projections." 15 Journal of Public Administration Research and Theory 281-306.
28. Kyle, Margaret. 2006. "The Role of Firm Characteristics in Pharmaceutical Product Launches," 37 RAND Journal of Economics 602-18.
29. Law, Marc T. 2006. "How do Regulators Regulate? Enforcement of the Pure Food and Drugs Act, 1907-38," 22 Journal of Law, Economics, and Organization 459-89.
30. Law, Marc T., and Mindy S. Marks. 2007. "The Effects of Occupational Licensing Laws on Minorities: Evidence from the Progressive Era." Manuscript, Department of Economics, University of Vermont. SSRN Working Paper No. 943765.
31. Law, Marc T., and Sukkoo Kim. 2005. "Specialization and Regulation: The Rise of Professionals and the Emergence of Occupational Licensing Regulation," 65 Journal of Economic History 723-56.
32. Olson, Mary. 1995. "Substitution in Regulatory Agencies: FDA Enforcement Alternatives," 12 Journal of Law Economics and Organization 376-407.
33. -. 1997. "Firm Characteristics and the Speed of FDA Approval," 6 Journal of Economics and Management Strategy 377-401.
34. -. 2004. "Are Novel Drugs More Risky for Patients than Less Novel Drugs?" 23 Journal of Health Economics 1135-58.
35. Peltzman, Sam. 1973. "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments," 81 Journal of Political Economy 1049-91.
36. -. 1976. "Toward a More General Theory of Regulation," 19 Journal of Law and Economics 211-40.
37. Quirk, Paul. 1980. "The Food and Drug Administration," in James Q. Wilson, ed., The Politics of Regulation. New York: Basic Books.
38. Rothenberg, Lawrence S. 1994. Regulation, Organizations, and Politics: Motor Freight Policy at the Interstate Commerce Commission. Ann Arbor, MI: University of Michigan.
39. Spence, David B. 1999. "Managing Delegation Ex Ante: Using Law to Steer Administrative Agencies," 28 Journal of Legal Studies 413-60.
40. Stigler, George J. 1975. The Citizen and the State: Essays on Regulation. Chicago: University of Chicago Press.
41. Taylor, Howard M., and Samuel Karlin. 1998. An Introduction to Stochastic Modeling. 3rd ed. New York: Academic Press.
42. Thomas, Lacy Glenn. 1990. "Regulation and Firm Size: FDA Impacts on Innovation," 21 RAND Journal of Economics 497-517.
43. Vogel, David. 1996. Kindred Strangers: The Uneasy Relationship between Politics and Business in America. Chapter 8. Princeton: Princeton University Press.
44. Wilson, James Q. 1980. The Politics of Regulation. New York: Basic Books.